The Weight Management Program is a provider-supervised offering that may include tirzepatide (a GLP-1 / GIP receptor agonist) and, where clinically appropriate, an additional compounded option. Whether this program is appropriate and which medication is prescribed is determined by a licensed provider during a consultation that reviews your medical history, eligibility, and contraindications. Outcomes vary by individual.
About this program
Tirzepatide is the active ingredient in certain branded medications, including Mounjaro® and Zepbound®. Brand names are referenced for educational context only and do not indicate that a specific branded product will be prescribed. If a compounded formulation is prescribed for you, it is prepared by a state-licensed compounding pharmacy pursuant to a valid prescription.
What your provider may discuss during consultation
- Whether GLP-1 / GIP therapy may align with your individual goals
- Eligibility, contraindications, and risks
- Lifestyle integration, adherence, and follow-up
- Monitoring schedule and laboratory work, as appropriate
Individual response varies. No specific outcome is promised. Not all patients are candidates.
Important Information About This Program
This program includes prescription medication. Eligibility, dosing, and continuation are determined by a licensed provider after a clinical consultation. Booking a consultation does not mean medication will be prescribed. Treatment is not appropriate for everyone — including patients with a personal or family history of medullary thyroid carcinoma, MEN-2, pancreatitis, pregnancy or breastfeeding, among other conditions.
Medication Status. Branded GLP-1 / GIP medications are prescribed for specific clinical uses when appropriate. If a compounded formulation is prescribed for you, it is prepared by a state-licensed compounding pharmacy pursuant to a valid prescription.
Side Effects. Possible side effects can include nausea, vomiting, diarrhea, constipation, and abdominal pain. Serious risks have been described in FDA labeling. Your provider will review the full risk profile during consultation.
Individual Response. Outcomes vary from patient to patient. We do not promise any specific outcome.
Reporting Adverse Events. If you experience a side effect, contact us, your prescribing provider, and FDA MedWatch at https://www.fda.gov/safety/medwatch.
Emergencies. This site and our telehealth services are not for medical emergencies. Call 911 in a medical emergency.
Provider Review: Our weight management program includes provider-guided evaluations, ongoing monitoring, and personalized treatment recommendations based on individual health needs and goals.
Eligibility: Participation in the program is subject to medical review. Treatment recommendations vary based on patient history, health status, and provider assessment.
Results: Results differ from person to person and are influenced by factors including metabolism, nutrition, physical activity, and consistency with treatment plans.
